US2002159977A1PendingUtilityA1

Adeno-associated vector compositions for expression of factor VIII

56
Priority: Mar 24, 1999Filed: Nov 16, 2001Published: Oct 31, 2002
Est. expiryMar 24, 2019(expired)· nominal 20-yr term from priority
C12N 2750/14143C12N 2799/025C12N 2830/008C12N 15/86A61P 7/04A61K 48/00C12N 2830/85A61K 38/37C12N 2830/42C07K 14/755
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

One form of a composition has two types of recombinant adeno-associated virus. The first type encodes a portion of Factor VIII operably linked to an expression control element; and the second type encodes a different portion of Factor VIII operably linked to an expression control element. The first and second nucleotide sequences collectively encode a functional Factor VIII protein. Another form of the composition is a recombinant adeno-associated virus containing a nucleotide sequence encoding functional Factor VIII light or heavy chain operably linked to a tissue-specific promoter.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method of treating hemophilia in a human comprsing provding at least one recombinant adeno-associated virion comprising nucleotide sequences encoding Factor VIII and administering said at least one recombinant adeno-associated virion into said human under conditions such that said Factor VIII nucleotide sequences are expressed at a level which provides a therapeutically effective amount in said human.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.